Analysts expect Halozyme Therapeutics, Inc. to report revenue of 461.43 M for Q3 26, against a range of 432.26 M to 490.59 M. The most recent reported quarter, Q2 26, came in at 481.00 M, a 25.4% beat against the 383.55 M consensus.
| Metric | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 290.08 M | 298.01 M | 264.86 M | 325.72 M | 354.26 M | 451.77 M | 376.71 M | 481.00 M | - | - | - | - | - | - | - | - | ||||||||||
| High Estimate | 247.47 M | 280.50 M | 239.45 M | 322.36 M | 358.07 M | 454.98 M | 350.02 M | 411.79 M | 490.59 M | 524.67 M | 468.65 M | 558.12 M | 556.95 M | 681.14 M | 526.20 M | 628.88 M | ||||||||||
| Low Estimate | 226.02 M | 251.46 M | 208.95 M | 282.29 M | 293.35 M | 379.14 M | 322.35 M | 355.31 M | 432.26 M | 492.59 M | 435.72 M | 510.62 M | 511.55 M | 575.55 M | 448.12 M | 530.75 M | ||||||||||
| Consensus Estimate | 236.75 M | 265.98 M | 224.20 M | 302.33 M | 325.71 M | 417.06 M | 336.18 M | 383.55 M | 461.43 M | 508.63 M | 452.18 M | 534.37 M | 534.25 M | 628.35 M | 487.16 M | 579.81 M |
Analysts expect Halozyme Therapeutics, Inc. to report earnings per share of 2.44 for Q3 26, against a range of 2.30 to 2.58. The most recent reported quarter, Q2 26, came in at 2.28, a 31.0% beat against the 1.74 consensus.
| Metric | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 1.27 | 1.26 | 1.11 | 1.54 | 1.72 | -0.24 | 1.60 | 2.28 | - | - | - | - | - | - | - | - | ||||||||||
| High Estimate | 1.14 | 1.28 | 0.99 | 1.37 | 1.64 | 2.46 | 1.56 | 1.81 | 2.58 | 2.81 | 2.40 | 2.56 | 3.09 | 3.03 | 2.81 | 3.52 | ||||||||||
| Low Estimate | 0.98 | 1.14 | 0.83 | 1.23 | 1.46 | 2.18 | 1.42 | 1.67 | 2.30 | 2.47 | 1.96 | 2.14 | 2.57 | 2.55 | 2.57 | 2.96 | ||||||||||
| Consensus Estimate | 1.06 | 1.21 | 0.91 | 1.30 | 1.55 | 2.32 | 1.49 | 1.74 | 2.44 | 2.64 | 2.18 | 2.35 | 2.83 | 2.79 | 2.69 | 3.24 |
Pull Wall Street consensus for Halozyme Therapeutics, Inc. (high, low and consensus estimates alongside reported actuals) into your own models and apps with the Business Quant Estimates API. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/estimates?ticker=HALO&mode=revenue&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/estimates"
params = {"ticker": "HALO", "mode": "revenue", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/estimates?ticker=HALO&mode=revenue&api_key=YOUR_API_KEY");
const data = await res.json();